Report topline results from Phase 3 acne clinical study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 2 Jan 2025
- Due
- 30 Jun 2025
- Delivered
- 4 Jun 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Phase 3 clinical study enrollment completed in Nov 2024; topline results expected in 2Q2025”
What we found
Evidence strength B What the grades mean
Sagimet reported positive Phase 3 topline results for denifanstat in acne (via partner Ascletis) on June 4, 2025, within the stated 2Q2025 window.
-
B Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis IR page confirming June 4, 2025 topline Phase 3 acne results
-
B Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis Company press release reporting topline Phase 3 acne results met all endpoints
-
C Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis - BioSpace News coverage confirming topline results delivered June 4, 2025
Checked 12 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Language
- Expected (“expects”, “plans”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Sagimet Biosciences Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-SGMT-000008 · Corrections policy